Apixaban (Anticoagulation for AFib-related stroke)
Treatment for Ischemic Stroke
Typical Dosage: 5 mg BID
Effectiveness
70%
Safety Score
65%
Clinical Trials
10
Participants
70K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg BID
Time to Effect
days
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
30(Treat 30 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,000
Monitoring:$150
Side Effect Mgmt:$300
Total Annual:$6,450
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$45,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$9,923
Comparison vs Warfarin
Cost Difference
+$5,500/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Apixaban (Anticoagulation for AFib-related stroke) Outcomes
for Ischemic Stroke
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+65%
Common Side Effects
Major bleeding (ICH, GI)
+2%
Minor bleeding
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov